Office of New Drugs

Office of New Drugs, Center for Drug Evaluation and Research Food and Drug Administration Rockville, MD 20857... 

Applications for marketing should be sent to MHLW. The application then passes to PMDA, where the application splits into two different routes, namely (1) good laboratory practice (GLP), GCP and reliability compliance check by Office of Conformity Audit and (2) application review by Offices of New Drug or Office of Biologies. 

It s the clinical trials that take so long—usually several years, says Sandra Kweder, M.D., deputy director of the Office of New Drugs in the CDER. The emphasis on speed for FDA mostly relates to review time and timelines of being able to meet with sponsors during a drug s development, she says. 

John Jenkins, M.D., director of CDER s Office of New Drugs, says, It s often a combination of problems that prevent approval. Close... 

Branch V Division of Pre-marketing Assessment and Manufacturing Science, Office of New Drug Quality Assessment, Office of Pharmaceutical Science, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD 20993... 

CDER has a larger product development responsibility than CBER, and thus has five Therapeutic Review Divisions, each led by a career civil servant Division Director. But the other divisions are similar to the CBER model, with divisions for Epidemiology and Statistics, Compliance, Pharmaceutical Sciences (including a specialized office of New Drug Chemistry), Biopharmaceutics and Generic Drugs. It seems likely that an Office for Toxicology will soon be established. 

Office of New Drug I. This division takes in charge anti-HIV agents, anti-malignant tumor agents, anti-bacterial agents and related drugs. 

Providing scientific oversight, through the Center s Office of New Drug Chemistry, of... 

ODN see oligonucleotide/oligodeoxynucleotide Office of new drug chemistry (ONDC) 1639 Offilce of new drugs (OND) 1639 Office of regulatory affairs (ORA) 1639 Office of therapeutics research and review (OTRR) 1639... 

Figure 8.11 includes more details, more complex feedback loops, and more outside pressures, such as the availability of a replacement drug, the time left on the drug s patent, and the amount of time spent on drug development. Pressures on the FDA from the pharmaceutical companies are elaborated including the pressures on the Office of New Drugs (OND) through PDUFA fees, pressures from advisory boards... 

---